TDXD and HER2 Mutant Lung Cancer - What Are the Side Effects?

The mechanism of action is quite different compared to the EGFR TKI's. So I'd see it like a smart targeted chemotherapy, so to speak. The response rates have been about 50 to 60%. And interestingly, some of my patients, you know, even treated off protocol, they've some of them respond very quickly in the first scan and get a partial response. Some of my patients actually get stable disease for a year and a half before they start to get an immune response. But again, this is a little bit different. You have to look at the full picture. In a refractory setting, you're seeing a median PFS of progression free survival about eight months.